128 related articles for article (PubMed ID: 29603140)
1. Differences in the placebo response in duloxetine and venlafaxine trials.
Breilmann J; Furukawa TA; Becker T; Koesters M
Acta Psychiatr Scand; 2018 Jun; 137(6):472-480. PubMed ID: 29603140
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
Eckert L; Lançon C
BMC Psychiatry; 2006 Jul; 6():30. PubMed ID: 16867188
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.
Schueler YB; Koesters M; Wieseler B; Grouven U; Kromp M; Kerekes MF; Kreis J; Kaiser T; Becker T; Weinmann S
Acta Psychiatr Scand; 2011 Apr; 123(4):247-65. PubMed ID: 20831742
[TBL] [Abstract][Full Text] [Related]
4. How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients?
Uçan Gündüz G; Parmak Yener N; Kılınçel O; Gündüz C
J Ocul Pharmacol Ther; 2018 May; 34(4):354-359. PubMed ID: 29446702
[TBL] [Abstract][Full Text] [Related]
5. Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Noma H; Furukawa TA; Maruo K; Imai H; Shinohara K; Tanaka S; Ikeda K; Yamawaki S; Cipriani A
J Affect Disord; 2019 May; 250():419-424. PubMed ID: 30878654
[TBL] [Abstract][Full Text] [Related]
6. Differences in the antinociceptive effects of serotonin-noradrenaline reuptake inhibitors via sodium channel blockade using the veratrine test in mice.
Yoshizawa K; Suzuki Y; Nakamura T; Takahashi Y; Makino K; Takahashi H
Neuroreport; 2021 Jun; 32(9):797-802. PubMed ID: 33994525
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
[TBL] [Abstract][Full Text] [Related]
8. Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.
Kim HK; Tyryshkin K; Elmi N; Dharsee M; Evans KR; Good J; Javadi M; McCormack S; Vaccarino AL; Zhang X; Andreazza AC; Feilotter H
J Psychiatr Res; 2019 Mar; 110():38-44. PubMed ID: 30580082
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
Xu Y; Bai SJ; Lan XH; Qin B; Huang T; Xie P
Braz J Med Biol Res; 2016 May; 49(6):. PubMed ID: 27240293
[TBL] [Abstract][Full Text] [Related]
11. Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay.
Islin J; Munkboel CH; Styrishave B
Toxicol In Vitro; 2018 Mar; 47():63-71. PubMed ID: 29100959
[TBL] [Abstract][Full Text] [Related]
12. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.
Lassen D; Ennis ZN; Damkier P
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):32-6. PubMed ID: 26435496
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.
Farshchian N; Alavi A; Heydarheydari S; Moradian N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):787-793. PubMed ID: 30105459
[TBL] [Abstract][Full Text] [Related]
14. Fatal overdose with a combination of SNRIs venlafaxine and duloxetine.
Alibegović A; Kariž S; Volavšek M
Forensic Sci Med Pathol; 2019 Jun; 15(2):258-261. PubMed ID: 30796754
[TBL] [Abstract][Full Text] [Related]
15. Systematic evaluation of the 'efficacy-effectiveness gap' in the treatment of depression with venlafaxine and duloxetine.
Schneider C; Breilmann J; Reuter B; Becker T; Kösters M
Acta Psychiatr Scand; 2021 Aug; 144(2):113-124. PubMed ID: 33661520
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
17. GWAS-based machine learning approach to predict duloxetine response in major depressive disorder.
Maciukiewicz M; Marshe VS; Hauschild AC; Foster JA; Rotzinger S; Kennedy JL; Kennedy SH; Müller DJ; Geraci J
J Psychiatr Res; 2018 Apr; 99():62-68. PubMed ID: 29407288
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
19. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
